向临床医生提示心衰住院患者1年死亡风险:REVEAL-HF随机临床试验
REVEAL-HF是一项在耶鲁纽黑文健康系统开展的实用型多中心电子病历随机试验,纳入因心衰住院且NT-proBNP>500 pg/mL并在入院24小时内接受静脉利尿剂的患者3124例,随机分为预警组(1590例)和常规护理组(1534例)。预警组通过基于电子病历历史数据推导并验证的算法计算1年死亡风险并呈现给临床医生。
要点
- 提供1年死亡风险预警未改善心衰住院患者的再入院或死亡复合终点。
- 预警未显著改变出院心衰药物处方、ICD植入或姑息治疗转诊决策。
- 风险模型在试验人群中AUC为0.74,但未转化为临床决策改善。
核心结论
- 在心衰住院期间向临床医生提供1年死亡风险估计未影响住院或死亡,也未影响临床决策。
研究设计与样本
- 实用型、多中心、基于电子病历的随机临床试验,覆盖耶鲁纽黑文健康系统的小社区医院和大型三级中心。
- 纳入因心衰住院且NT-proBNP>500 pg/mL并在入院24小时内接受静脉利尿剂的患者,自动随机分为预警组(1590例)和常规护理组(1534例)。
主要发现
- 两组在出院时心衰药物处方、植入式心律转复除颤器植入或姑息治疗转诊方面无显著差异。
- 风险模型在试验人群中的AUC为0.74。
临床怎么用
- 基于电子病历的1年死亡风险预警未显示出改善心衰住院患者临床决策或结局的作用。
- 临床医生不应仅依赖此类风险提示来改变心衰住院期间的治疗强度或姑息治疗转诊决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Heart failure is a major cause of morbidity and mortality worldwide. The use of risk scores has the potential to improve targeted use of interventions by clinicians that improve patient outcomes, but this hypothesis has not been tested in a randomized trial. OBJECTIVE: To evaluate whether prognostic information in heart failure translates into improved decisions about initiation and intensity of treatment, more appropriate end-of-life care, and a subsequent reduction in rates of hospitalization or death. DESIGN, SETTING, AND PARTICIPANTS: This was a pragmatic, multicenter, electronic health record-based, randomized clinical trial across the Yale New Haven Health System, comprising small community hospitals and large tertiary care centers. Patients hospitalized for heart failure who had N-terminal pro-brain natriuretic peptide (NT-proBNP) levels of greater than 500 pg/mL and received intravenous diuretics within 24 hours of admission were automatically randomly assigned to the alert (intervention) or usual-care groups. INTERVENTIONS: The alert group had their risk of 1-year mortality calculated using an algorithm that was derived and validated using similar historic patients in the electronic health record. This estimate, including a categorical risk assessment, was presented to clinicians while they were interacting with a patient's electronic health record. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of 30-day hospital readmissions and all-cause mortality at 1 year. RESULTS: Between November 27, 2019, through March 7, 2021, 3124 patients were randomly assigned to the alert (1590 [50.9%]) or usual-care (1534 [49.1%]) group. The alert group had a median (IQR) age of 76.5 (65-86) years, and 796 were female patients (50.1%). Patients from the following race and ethnicity groups were included: 13 Asian (0.8%), 324 Black (20.4%), 136 Hispanic (8.6%), 1448 non-Hispanic (91.1%), 1126 White (70.8%), 6 other ethnicity (0.4%), and 127 other race (8.0%). The usual-care group had a median (IQR) age of 77 (65-86) years, and 788 were female patients (51.4%). Patients from the following race and ethnicity groups were included: 11 Asian (1.4%), 298 Black (19.4%), 162 Hispanic (10.6%), 1359 non-Hispanic (88.6%), 1077 White (70.2%), 13 other ethnicity (0.9%), and 137 other race (8.9%). Median (IQR) NT-proBNP levels were 3826 (1692-8241) pg/mL in the alert group and 3867 (1663-8917) pg/mL in the usual-care group. A total of 284 patients (17.9%) and 270 patients (17.6%) were admitted to the intensive care unit in the alert and usual-care groups, respectively. A total of 367 patients (23.1%) and 359 patients (23.4%) had a left ventricular ejection fraction of 40% or less in the alert and usual-care groups, respectively. The model achieved an area under the curve of 0.74 in the trial population. The primary outcome occurred in 619 patients (38.9%) in the alert group and 603 patients (39.3%) in the usual-care group (P = .89). There were no significant differences between study groups in the prescription of heart failure medications at discharge, the placement of an implantable cardioverter-defibrillator, or referral to palliative care. CONCLUSIONS AND RELEVANCE: Provision of 1-year mortality estimates during heart failure hospitalization did not affect hospitalization or mortality, nor did it affect clinical decision-making. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03845660.
引用
- Ahmad, Desai, Yamamoto, et al. Alerting Clinicians to 1-Year Mortality Risk in Patients Hospitalized With Heart Failure: The REVEAL-HF Randomized Clinical Trial. JAMA Cardiol. 2022. PMID: 35947362. doi:10.1001/jamacardio.2022.2496
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。